{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,5]],"date-time":"2026-07-05T08:31:22Z","timestamp":1783240282893,"version":"3.54.6"},"reference-count":134,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T00:00:00Z","timestamp":1547164800000},"content-version":"am","delay-in-days":375,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Ackerman Foundation"},{"name":"Barbara and Brian Nicholoff"},{"name":"Catabasis"},{"DOI":"10.13039\/100008572","name":"University of Ottawa Research Chair Award","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008572","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CHEO Departments of Pediatrics and Surgery"},{"name":"CHEO Research Institute Research Capacity Building Award"},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01-AR059357"],"award-info":[{"award-number":["R01-AR059357"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32-AR065971"],"award-info":[{"award-number":["T32-AR065971"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Veterans Administration","award":["1 I01 BX002104-01"],"award-info":[{"award-number":["1 I01 BX002104-01"]}]},{"DOI":"10.13039\/100000005","name":"DOD","doi-asserted-by":"publisher","award":["MD120063"],"award-info":[{"award-number":["MD120063"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"NIH-NIA","doi-asserted-by":"publisher","award":["P01 AG039355"],"award-info":[{"award-number":["P01 AG039355"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]},{"name":"George and Hazel Jay Endowment Fund"},{"name":"UT System Science and Technology Acquisition and Retention Program"},{"DOI":"10.13039\/100000049","name":"NIH-NIA","doi-asserted-by":"publisher","award":["PO1 AG039355"],"award-info":[{"award-number":["PO1 AG039355"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","nmd-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuromuscular Disorders"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.nmd.2017.05.012","type":"journal-article","created":{"date-parts":[[2017,5,15]],"date-time":"2017-05-15T15:31:34Z","timestamp":1494862294000},"page":"64-76","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Proceedings of a Parent Project Muscular Dystrophy Bone Health Workshop"],"prefix":"10.1016","volume":"28","author":[{"given":"Leanne M.","family":"Ward","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathi","family":"Kinnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Bonewald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan D.","family":"Adachi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Bachrach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresita","family":"Bellido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Brotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynda","family":"Bonewald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Donovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathi","family":"Kinnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugh","family":"McMillan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Novotny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Rafael-Fortney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Rauch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leanne","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Warden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nmd.2017.05.012_bib0010","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.23528","article-title":"Evidence-based path to newborn screening for Duchenne muscular dystrophy","volume":"71","author":"Mendell","year":"2012","journal-title":"Ann Neurol"},{"key":"10.1016\/j.nmd.2017.05.012_bib0015","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.nmd.2014.03.008","article-title":"A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy","volume":"24","author":"Mah","year":"2014","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2017.05.012_bib0020","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jpeds.2009.02.007","article-title":"Delayed diagnosis in Duchenne muscular dystrophy: data from the Muscular Dystrophy Surveillance, Tracking, and Research Network (MD STARnet)","volume":"155","author":"Ciafaloni","year":"2009","journal-title":"J Pediatr"},{"key":"10.1016\/j.nmd.2017.05.012_bib0025","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S1474-4422(09)70271-6","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management","volume":"9","author":"Bushby","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2017.05.012_bib0030","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.nmd.2013.04.005","article-title":"Motor and cognitive assessment of infants and young boys with Duchenne Muscular Dystrophy: results from the Muscular Dystrophy Association DMD Clinical Research Network","volume":"23","author":"Connolly","year":"2013","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2017.05.012_bib0035","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1212\/WNL.0000000000001950","article-title":"Prednisone\/prednisolone and deflazacort regimens in the CINRG Duchenne natural history study","volume":"85","author":"Bello","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2017.05.012_bib0040","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1474-4422(09)70272-8","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care","volume":"9","author":"Bushby","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2017.05.012_bib0045","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1056\/NEJM198906153202405","article-title":"Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy","volume":"320","author":"Mendell","year":"1989","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2017.05.012_bib0050","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 1: updated recommendations on diagnosis, neuromuscular, rehabilitation, endocrine and nutritional management","author":"Birnkrant","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2017.05.012_bib0055","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.nmd.2016.08.011","article-title":"Bone health measures in glucocorticoid-treated ambulatory boys with Duchenne muscular dystrophy","volume":"26","author":"Tian","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2017.05.012_bib0060","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s00198-016-3774-5","article-title":"The time to and determinants of first fractures in boys with Duchenne muscular dystrophy","volume":"28","author":"Ma","year":"2017","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.nmd.2017.05.012_bib0065","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(18)30025-5","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 2: updated recommendations on respiratory, cardiac, bone health and orthopedic\/surgical management","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2017.05.012_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(18)30026-7","article-title":"Diagnosis and management of Duchenne muscular dystrophy, part 3: updated care considerations on primary care and emergency medicine, psychosocial care, and transitions of care across the lifespan","author":"Birnkrant","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2017.05.012_bib0075","author":"Parent Project Muscular Dystrophy"},{"key":"10.1016\/j.nmd.2017.05.012_bib0080","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/01241398-200001000-00016","article-title":"Bone mineral density and fractures in boys with Duchenne muscular dystrophy","volume":"20","author":"Larson","year":"2000","journal-title":"J Pediatr Orthop"},{"key":"10.1016\/j.nmd.2017.05.012_bib0085","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1469-8749.2002.tb00272.x","article-title":"Fracture prevalence in Duchenne muscular dystrophy","volume":"44","author":"McDonald","year":"2002","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.nmd.2017.05.012_bib0090","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1212\/01.wnl.0000260974.41514.83","article-title":"Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy","volume":"68","author":"King","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2017.05.012_bib0095","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1200\/JCO.2011.40.4830","article-title":"High incidence of vertebral fractures in children with acute lymphoblastic leukemia 12 months after the initiation of therapy","volume":"30","author":"Alos","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.nmd.2017.05.012_bib0100","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1002\/acr.20589","article-title":"Incident vertebral fractures among children with rheumatic disorders 12 months after glucocorticoid initiation: a national observational study","volume":"64","author":"Rodd","year":"2012","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.nmd.2017.05.012_bib0105","doi-asserted-by":"crossref","first-page":"3408","DOI":"10.1210\/JC.2015-2176","article-title":"Incident vertebral fractures in children with leukemia during the four years following diagnosis","volume":"100","author":"Cummings","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.nmd.2017.05.012_bib0110","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/jbmr.2511","article-title":"Incident vertebral fractures and risk factors in the first three years following glucocorticoid initiation among pediatric patients with rheumatic disorders","volume":"30","author":"LeBlanc","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.nmd.2017.05.012_bib0115","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1212\/WNL.0b013e31828ab313","article-title":"Fat embolism syndrome in patients with Duchenne muscular dystrophy","volume":"80","author":"Medeiros","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2017.05.012_bib0120","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.nmd.2012.07.010","article-title":"Fat embolism syndrome following minor trauma in Duchenne muscular dystrophy","volume":"22","author":"McAdam","year":"2012","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2017.05.012_bib0125","doi-asserted-by":"crossref","first-page":"e353","DOI":"10.1542\/peds.2010-1666","article-title":"Impact of bisphosphonates on survival for patients with Duchenne muscular dystrophy","volume":"127","author":"Gordon","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.nmd.2017.05.012_bib0130","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s00198-016-3515-9","article-title":"The management of osteoporosis in children","volume":"27","author":"Ward","year":"2016","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.nmd.2017.05.012_bib0135","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","article-title":"Vertebral fracture assessment using a semiquantitative technique","volume":"8","author":"Genant","year":"1993","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.nmd.2017.05.012_bib0140","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/000992280304200408","article-title":"Vertebral fractures in boys with Duchenne muscular dystrophy","volume":"42","author":"Bothwell","year":"2003","journal-title":"Clin Pediatr (Phila)"},{"key":"10.1016\/j.nmd.2017.05.012_bib0145","doi-asserted-by":"crossref","first-page":"2703","DOI":"10.1007\/s00198-012-1911-3","article-title":"The use of intravenous bisphosphonate therapy to treat vertebral fractures due to osteoporosis among boys with Duchenne muscular dystrophy","volume":"23","author":"Sbrocchi","year":"2012","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.nmd.2017.05.012_bib0150","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1469-8749.2009.03464.x","article-title":"Low bone mass in patients with motor disability: prevalence and risk factors in 59 Finnish children","volume":"52","author":"Kilpinen-Loisa","year":"2010","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.nmd.2017.05.012_bib0155","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1359\/jbmr.090202","article-title":"Advanced vertebral fracture among newly diagnosed children with acute lymphoblastic leukemia: results of the Canadian Steroid-Associated Osteoporosis in the Pediatric Population (STOPP) research program","volume":"24","author":"Halton","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.nmd.2017.05.012_bib0160","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s11914-010-0031-2","article-title":"Biomechanics of vertebral fractures and the vertebral fracture cascade","volume":"8","author":"Christiansen","year":"2010","journal-title":"Curr Osteoporos Rep"},{"key":"10.1016\/j.nmd.2017.05.012_bib0165","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1210\/jc.2014-3096","article-title":"The choice of normative pediatric reference database changes spine bone mineral density Z-scores but not the relationship between bone mineral density and prevalent vertebral fractures","volume":"100","author":"Ma","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.nmd.2017.05.012_bib0170","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jocd.2014.01.004","article-title":"Fracture prediction and the definition of osteoporosis in children and adolescents: the ISCD 2013 pediatric official positions","volume":"17","author":"Bishop","year":"2014","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.nmd.2017.05.012_bib0175","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jocd.2009.01.005","article-title":"Revised pediatric reference data for the lateral distal femur measured by Hologic Discovery\/Delphi dual-energy X-ray absorptiometry","volume":"12","author":"Zemel","year":"2009","journal-title":"J Clin Densitom"},{"key":"10.1016\/j.nmd.2017.05.012_bib0180","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s00198-013-2460-0","article-title":"Mild morphometric vertebral fractures predict vertebral fractures but not non-vertebral fractures","volume":"25","author":"Johansson","year":"2014","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.nmd.2017.05.012_bib0185","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1359\/JBMR.041232","article-title":"Intravenous neridronate in children with osteogenesis imperfecta: a randomized controlled study","volume":"20","author":"Gatti","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.nmd.2017.05.012_bib0190","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jpeds.2006.03.013","article-title":"Early bisphosphonate treatment in infants with severe osteogenesis imperfecta","volume":"149","author":"Antoniazzi","year":"2006","journal-title":"J Pediatr"},{"key":"10.1016\/j.nmd.2017.05.012_bib0195","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/adc.2006.096552","article-title":"Intravenous pamidronate treatment of infants with severe osteogenesis imperfecta","volume":"92","author":"Astrom","year":"2007","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.nmd.2017.05.012_bib0200","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1002\/jbmr.2567","article-title":"Intravenous bisphosphonate therapy of young children with osteogenesis imperfecta: skeletal findings during follow up throughout the growing years","volume":"30","author":"Palomo","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.nmd.2017.05.012_bib0205","first-page":"91","article-title":"Cyclic administration of pamidronate to treat osteoporosis in children with cerebral palsy or a neuromuscular disorder: a clinical study","volume":"71","author":"Allington","year":"2005","journal-title":"Acta Orthop Belg"},{"key":"10.1016\/j.nmd.2017.05.012_bib0210","first-page":"0","article-title":"A randomized, placebo-controlled trial of oral alendronate in children and adolescents with osteogenesis imperfecta","volume":"36","author":"Ward","year":"2005","journal-title":"Bone"},{"key":"10.1016\/j.nmd.2017.05.012_bib0215","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1359\/jbmr.090213","article-title":"Risedronate in the treatment of mild pediatric osteogenesis imperfecta: a randomized placebo-controlled study","volume":"24","author":"Rauch","year":"2009","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.nmd.2017.05.012_bib0220","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S0140-6736(04)16101-1","article-title":"Skeletal effects and functional outcome with olpadronate in children with osteogenesis imperfecta: a 2-year randomised placebo-controlled study","volume":"363","author":"Sakkers","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.nmd.2017.05.012_bib0225","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1146\/annurev-genom-090314-025003","article-title":"The pathogenesis and therapy of muscular dystrophies","volume":"16","author":"Guiraud","year":"2015","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"10.1016\/j.nmd.2017.05.012_bib0230","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1161\/CIRCULATIONAHA.114.015151","article-title":"Contemporary cardiac issues in Duchenne muscular dystrophy. Working Group of the National Heart, Lung, and Blood Institute in collaboration with Parent Project Muscular Dystrophy","volume":"131","author":"McNally","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.nmd.2017.05.012_bib0235","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1474-4422(14)70318-7","article-title":"Eplerenone for early cardiomyopathy in Duchenne muscular dystrophy: a randomised, double-blind, placebo-controlled trial","volume":"14","author":"Raman","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2017.05.012_bib0240","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.bone.2015.01.005","article-title":"Decreases in bone mineral density at cortical and trabecular sites in the tibia and femur during the first year of spinal cord injury","volume":"74","author":"Coupaud","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.nmd.2017.05.012_bib0245","first-page":"264","article-title":"Effect of a single botulinum toxin injection on bone development in growing rabbits","volume":"6","author":"Rauch","year":"2006","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"10.1016\/j.nmd.2017.05.012_bib0250","first-page":"26","article-title":"Effect on maximal strength of submaximal exercise in Duchenne muscular dystrophy","volume":"58","author":"de Lateur","year":"1979","journal-title":"Am J Phys Med"},{"key":"10.1016\/j.nmd.2017.05.012_bib0255","first-page":"174","article-title":"Effect of exercise in Duchenne muscular dystrophy","volume":"67","author":"Scott","year":"1981","journal-title":"Physiotherapy"},{"key":"10.1016\/j.nmd.2017.05.012_bib0260","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.1966.03110110067015","article-title":"The effect of exercise in muscular dystrophy","volume":"197","author":"Vignos","year":"1966","journal-title":"JAMA"},{"key":"10.1016\/j.nmd.2017.05.012_bib0265","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/mus.21141","article-title":"Adaptive and nonadaptive responses to voluntary wheel running by mdx mice","volume":"38","author":"Landisch","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2017.05.012_bib0270","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1249\/MSS.0b013e31825703f0","article-title":"Exercise training improves plantar flexor muscle function in mdx mice","volume":"44","author":"Baltgalvis","year":"2012","journal-title":"Med Sci Sports Exerc"},{"key":"10.1016\/j.nmd.2017.05.012_bib0275","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/mus.21764","article-title":"Progressive resistance voluntary wheel running in the mdx mouse","volume":"42","author":"Call","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2017.05.012_bib0280","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1152\/japplphysiol.00942.2011","article-title":"Adaptive strength gains in dystrophic muscle exposed to repeated bouts of eccentric contraction","volume":"111","author":"Call","year":"2011","journal-title":"J Appl Physiol"},{"key":"10.1016\/j.nmd.2017.05.012_bib0285","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1359\/jbmr.060612","article-title":"Low-level, high-frequency mechanical signals enhance musculoskeletal development of young women with low BMD","volume":"21","author":"Gilsanz","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.nmd.2017.05.012_bib0290","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1359\/JBMR.0301251","article-title":"Prevention of postmenopausal bone loss by a low-magnitude, high-frequency mechanical stimuli: a clinical trial assessing compliance, efficacy, and safety","volume":"19","author":"Rubin","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.nmd.2017.05.012_bib0295","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1359\/JBMR.0301245","article-title":"Effect of 6-month whole body vibration training on hip density, muscle strength, and postural control in postmenopausal women: a randomized controlled pilot study","volume":"19","author":"Verschueren","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.nmd.2017.05.012_bib0300","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1359\/JBMR.040129","article-title":"Low magnitude mechanical loading is osteogenic in children with disabling conditions","volume":"19","author":"Ward","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.nmd.2017.05.012_bib0305","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0104339","article-title":"Low intensity, high frequency vibration training to improve musculoskeletal function in a mouse model of Duchenne muscular dystrophy","volume":"9","author":"Novotny","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.nmd.2017.05.012_bib0310","article-title":"Feasibility and tolerability of low-intensity whole body vibration and its effects on muscle function and bone in patients with dystrophinopathies: a pilot study","author":"Petryk","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2017.05.012_bib0315","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/S0140-6736(74)90071-3","article-title":"Prednisone in Duchenne muscular dystrophy","volume":"2","author":"Drachman","year":"1974","journal-title":"Lancet"},{"key":"10.1016\/j.nmd.2017.05.012_bib0320","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1001\/archneur.1991.00530160047012","article-title":"Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group","volume":"48","author":"Griggs","year":"1991","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nmd.2017.05.012_bib0325","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/0960-8966(91)90099-E","article-title":"Steroids in Duchenne muscular dystrophy\u2013deflazacort trial","volume":"1","author":"Mesa","year":"1991","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2017.05.012_bib0330","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1067\/mpd.2001.109601","article-title":"Deflazacort treatment of Duchenne muscular dystrophy","volume":"138","author":"Biggar","year":"2001","journal-title":"J Pediatr"},{"key":"10.1016\/j.nmd.2017.05.012_bib0335","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00131402-200106000-00002","article-title":"Long-term steroid therapy in Duchenne muscular dystrophy-positive results versus side effects","volume":"2","author":"Schara","year":"2001","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1016\/j.nmd.2017.05.012_bib0340","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.ejpn.2006.12.002","article-title":"Predictive factors for the development of scoliosis in Duchenne muscular dystrophy","volume":"11","author":"Kinali","year":"2007","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.nmd.2017.05.012_bib0345","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2106\/00004623-200403000-00009","article-title":"Steroid treatment and the development of scoliosis in males with Duchenne muscular dystrophy","volume":"86-A","author":"Alman","year":"2004","journal-title":"J Bone Joint Surg Am"},{"key":"10.1016\/j.nmd.2017.05.012_bib0350","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.nmd.2008.03.002","article-title":"Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy","volume":"18","author":"Markham","year":"2008","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2017.05.012_bib0355","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1007\/s00246-005-0909-4","article-title":"Steroid therapy and cardiac function in Duchenne muscular dystrophy","volume":"26","author":"Markham","year":"2005","journal-title":"Pediatr Cardiol"},{"key":"10.1016\/j.nmd.2017.05.012_bib0360","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/S0002-9149(02)03429-X","article-title":"Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy","volume":"91","author":"Silversides","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.nmd.2017.05.012_bib0365","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1212\/01.WNL.0000148485.00049.B7","article-title":"Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society","volume":"64","author":"Moxley","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2017.05.012_bib0370","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1002\/1097-4598(200009)23:9<1344::AID-MUS4>3.0.CO;2-F","article-title":"A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy","volume":"23","author":"Bonifati","year":"2000","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2017.05.012_bib0375","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1001\/archneur.1991.00530180027012","article-title":"A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy","volume":"48","author":"Fenichel","year":"1991","journal-title":"Arch Neurol"},{"key":"10.1016\/j.nmd.2017.05.012_bib0380","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1083\/jcb.201212142","article-title":"The cell biology of disease: cellular and molecular mechanisms underlying muscular dystrophy","volume":"201","author":"Rahimov","year":"2013","journal-title":"J Cell Biol"},{"key":"10.1016\/j.nmd.2017.05.012_bib0385","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/345315a0","article-title":"Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle","volume":"345","author":"Ervasti","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.nmd.2017.05.012_bib0390","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1073\/pnas.90.8.3710","article-title":"Dystrophin protects the sarcolemma from stresses developed during muscle contraction","volume":"90","author":"Petrof","year":"1993","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.nmd.2017.05.012_bib0395","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1083\/jcb.200905048","article-title":"Dystrophin is a microtubule-associated protein","volume":"186","author":"Prins","year":"2009","journal-title":"J Cell Biol"},{"key":"10.1016\/j.nmd.2017.05.012_bib0400","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/372546a0","article-title":"Nitric oxide in skeletal muscle","volume":"372","author":"Kobzik","year":"1994","journal-title":"Nature"},{"key":"10.1016\/j.nmd.2017.05.012_bib0405","doi-asserted-by":"crossref","first-page":"ra56","DOI":"10.1126\/scisignal.2002829","article-title":"Microtubules underlie dysfunction in Duchenne muscular dystrophy","volume":"5","author":"Khairallah","year":"2012","journal-title":"Sci Signal"},{"key":"10.1016\/j.nmd.2017.05.012_bib0410","doi-asserted-by":"crossref","first-page":"13818","DOI":"10.1073\/pnas.250379497","article-title":"Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy","volume":"97","author":"Sander","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.nmd.2017.05.012_bib0415","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1212\/WNL.43.3_Part_1.520","article-title":"Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months)","volume":"43","author":"Griggs","year":"1993","journal-title":"Neurology"},{"key":"10.1016\/j.nmd.2017.05.012_bib0420","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S1474-4422(10)70196-4","article-title":"Treatment of Duchenne muscular dystrophy with ciclosporin A: a randomised, double-blind, placebo-controlled multicentre trial","volume":"9","author":"Kirschner","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.nmd.2017.05.012_bib0425","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/01.med.0000436249.84273.7b","article-title":"Glucocorticoid-related bone changes from endogenous or exogenous glucocorticoids","volume":"20","author":"Warriner","year":"2013","journal-title":"Curr Opin Endocrinol Diab Obes"},{"key":"10.1016\/j.nmd.2017.05.012_bib0430","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMra050541","article-title":"Antiinflammatory action of glucocorticoids\u2013new mechanisms for old drugs","volume":"353","author":"Rhen","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2017.05.012_bib0435","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMcp1012926","article-title":"Clinical practice. Glucocorticoid-induced bone disease","volume":"365","author":"Weinstein","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2017.05.012_bib0440","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1056\/NEJM199807303390502","article-title":"Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group","volume":"339","author":"Saag","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2017.05.012_bib0445","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00223-012-9630-5","article-title":"Management of glucocorticoid-induced osteoporosis","volume":"91","author":"Rizzoli","year":"2012","journal-title":"Calcif Tissue Int"},{"key":"10.1016\/j.nmd.2017.05.012_bib0450","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1530\/eje.0.1460051","article-title":"Increased risk of osteoporotic fractures in patients with Cushing's syndrome","volume":"146","author":"Vestergaard","year":"2002","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.nmd.2017.05.012_bib0455","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1210\/jc.2009-2161","article-title":"Muscle fiber conduction slowing and decreased levels of circulating muscle proteins after short-term dexamethasone administration in healthy subjects","volume":"95","author":"Minetto","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.nmd.2017.05.012_bib0460","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/mus.24572","article-title":"Quantitative and qualitative adaptations of muscle fibers to glucocorticoids","volume":"52","author":"Minetto","year":"2015","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2017.05.012_bib0465","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1677\/JOE-07-0606","article-title":"Mechanisms of glucocorticoid-induced myopathy","volume":"197","author":"Schakman","year":"2008","journal-title":"J Endocrinol"},{"key":"10.1016\/j.nmd.2017.05.012_bib0470","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.ecl.2012.04.004","article-title":"Glucocorticoid-induced osteoporosis and osteonecrosis","volume":"41","author":"Weinstein","year":"2012","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.nmd.2017.05.012_bib0475","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1172\/JCI0214538","article-title":"Promotion of osteoclast survival and antagonism of bisphosphonate-induced osteoclast apoptosis by glucocorticoids","volume":"109","author":"Weinstein","year":"2002","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nmd.2017.05.012_bib0480","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1172\/JCI2799","article-title":"Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone","volume":"102","author":"Weinstein","year":"1998","journal-title":"J Clin Invest"},{"key":"10.1016\/j.nmd.2017.05.012_bib0485","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/nm.3074","article-title":"WNT signaling in bone homeostasis and disease: from human mutations to treatments","volume":"19","author":"Baron","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.nmd.2017.05.012_bib0490","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1002\/jbmr.2869","article-title":"Protection from glucocorticoid-induced osteoporosis by anti-catabolic signaling in the absence of Sost\/sclerostin","volume":"31","author":"Sato","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.nmd.2017.05.012_bib0495","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/MED.0000000000000106","article-title":"Diagnosis and treatment of pediatric osteoporosis","volume":"21","author":"Bachrach","year":"2014","journal-title":"Curr Opin Endocrinol Diab Obes"},{"issue":"4","key":"10.1016\/j.nmd.2017.05.012_bib0500","article-title":"Bisphosphonate therapy for children and adolescents with secondary osteoporosis","author":"Ward","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.nmd.2017.05.012_bib0505","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005088.pub3","article-title":"Bisphosphonate therapy for osteogenesis imperfecta","author":"Dwan","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.nmd.2017.05.012_bib0510","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.apmr.2004.04.021","article-title":"Alendronate in the treatment of low bone mass in steroid-treated boys with Duchennes muscular dystrophy","volume":"86","author":"Hawker","year":"2005","journal-title":"Arch Phys Med Rehabil"},{"key":"10.1016\/j.nmd.2017.05.012_bib0515","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.anpedi.2010.10.002","article-title":"[Alendronate treatment of osteoporosis secondary to Duchenne muscular dystrophy]","volume":"74","author":"Palomo Atance","year":"2011","journal-title":"An Pediatr (Barc)"},{"key":"10.1016\/j.nmd.2017.05.012_bib0520","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1002\/mus.23948","article-title":"Bone density and alendronate effects in Duchenne muscular dystrophy patients","volume":"49","author":"Houston","year":"2014","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2017.05.012_bib0525","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/mus.24991","article-title":"Prophylactic oral bisphosphonate therapy in Duchenne muscular dystrophy","volume":"54","author":"Srinivasan","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.nmd.2017.05.012_bib0530","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1002\/jbmr.2805","article-title":"Recurrent proximal femur fractures in a teenager with osteogenesis imperfecta on continuous bisphosphonate therapy: are we overtreating?","volume":"31","author":"Vasanwala","year":"2016","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.nmd.2017.05.012_bib0535","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11832-011-0380-0","article-title":"Changing pattern of femoral fractures in osteogenesis imperfecta with prolonged use of bisphosphonates","volume":"6","author":"Nicolaou","year":"2012","journal-title":"J Child Orthop"},{"key":"10.1016\/j.nmd.2017.05.012_bib0540","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1210\/jc.2005-2413","article-title":"Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation","volume":"91","author":"Rauch","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.nmd.2017.05.012_bib0545","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"New Engl J Med"},{"key":"10.1016\/j.nmd.2017.05.012_bib0550","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"New Engl J Med"},{"key":"10.1016\/j.nmd.2017.05.012_bib0555","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.nmd.2017.05.012_bib0560","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1056\/NEJMoa1305224","article-title":"Romosozumab in postmenopausal women with low bone mineral density","volume":"370","author":"McClung","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2017.05.012_bib0565","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nmd.2017.05.012_bib0570","first-page":"183","article-title":"First use of the RANKL antibody denosumab in osteogenesis imperfecta type VI","volume":"12","author":"Semler","year":"2012","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"10.1016\/j.nmd.2017.05.012_bib0575","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13023-014-0145-1","article-title":"Two years' experience with denosumab for children with osteogenesis imperfecta type VI","volume":"9","author":"Hoyer-Kuhn","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.nmd.2017.05.012_bib0580","first-page":"24","article-title":"Safety and efficacy of denosumab in children with osteogenesis imperfect\u2013a first prospective trial","volume":"16","author":"Hoyer-Kuhn","year":"2016","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"10.1016\/j.nmd.2017.05.012_bib0585","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1210\/jc.2013-3081","article-title":"Effects of denosumab treatment and discontinuation on human growth plates","volume":"99","author":"Wang","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.nmd.2017.05.012_bib0590","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1359\/JBMR.040303","article-title":"Sclerotic metaphyseal lines in a child treated with pamidronate: histomorphometric analysis","volume":"19","author":"Rauch","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.nmd.2017.05.012_bib0595","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1002\/jbmr.1603","article-title":"Denosumab treatment for fibrous dysplasia","volume":"27","author":"Boyce","year":"2012","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.nmd.2017.05.012_bib0600","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s00774-015-0677-z","article-title":"Severe hypercalcemia following denosumab treatment in a juvenile patient","volume":"34","author":"Setsu","year":"2016","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.nmd.2017.05.012_bib0605","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/jbmr.410","article-title":"Mechanisms inducing low bone density in Duchenne muscular dystrophy in mice and humans","volume":"26","author":"Rufo","year":"2011","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.nmd.2017.05.012_bib0610","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/nm1054","article-title":"Selective inhibition of NF-kappa B blocks osteoclastogenesis and prevents inflammatory bone destruction in vivo","volume":"10","author":"Jimi","year":"2004","journal-title":"Nat Med"},{"key":"10.1016\/j.nmd.2017.05.012_bib0615","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/nm.1954","article-title":"Inhibition of osteoblastic bone formation by nuclear factor-kappaB","volume":"15","author":"Chang","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.nmd.2017.05.012_bib0620","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1021\/acs.jmedchem.5b01961","article-title":"Synthesis and characterization of fatty acid conjugates of niacin and salicylic acid","volume":"59","author":"Vu","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.nmd.2017.05.012_bib0625","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.nmd.2014.06.115","article-title":"G.P.101: CAT-1004, a novel anti-inflammatory agent under development for treatment of Duchenne muscular dystrophy","volume":"24","author":"Milne","year":"2014","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2017.05.012_bib0630","doi-asserted-by":"crossref","DOI":"10.1002\/jcph.842","article-title":"A novel NF-\u03baB inhibitor (Edasalonexent, CAT-1004) in development as a disease-modifying treatment for patients with Duchenne muscular dystrophy: phase 1 safety, pharmacokinetics, and pharmacodynamics in adult subjects","author":"Donovan","year":"2017","journal-title":"J Clin Pharmacol"},{"issue":"Suppl. 2","key":"10.1016\/j.nmd.2017.05.012_bib0635","doi-asserted-by":"crossref","first-page":"S157","DOI":"10.1016\/j.nmd.2016.06.260","article-title":"CAT-1004, an oral agent targeting NF-kB: MoveDMD trial results in Duchenne Muscular Dystrophy (DMD)","volume":"26","author":"Finanger","year":"2016","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.nmd.2017.05.012_bib0640","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/emmm.201302621","article-title":"VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects","volume":"5","author":"Heier","year":"2013","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.nmd.2017.05.012_bib0645","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.bone.2015.02.010","article-title":"Bone and muscle: interactions beyond mechanical","volume":"80","author":"Brotto","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.nmd.2017.05.012_bib0650","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2174\/1872208311206030223","article-title":"Prostaglandin E2: from clinical applications to its potential role in bone- muscle crosstalk and myogenic differentiation","volume":"6","author":"Mo","year":"2012","journal-title":"Recent Pat Biotechnol"},{"key":"10.1016\/j.nmd.2017.05.012_bib0655","doi-asserted-by":"crossref","first-page":"197","DOI":"10.22203\/eCM.v024a14","article-title":"Skeletal muscle secreted factors prevent glucocorticoid-induced osteocyte apoptosis through activation of beta-catenin","volume":"24","author":"Jahn","year":"2012","journal-title":"Eur Cell Mater"},{"key":"10.1016\/j.nmd.2017.05.012_bib0660","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/nm.3961","article-title":"Excess TGF-beta mediates muscle weakness associated with bone metastases in mice","volume":"21","author":"Waning","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.nmd.2017.05.012_bib0665","doi-asserted-by":"crossref","first-page":"4308","DOI":"10.1074\/jbc.M115.686626","article-title":"Deletion of Mbtps1 (Pcsk8, S1p, Ski-1) gene in osteocytes stimulates soleus muscle regeneration and increased size and contractile force with age","volume":"291","author":"Gorski","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.nmd.2017.05.012_bib0670","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/jbmr.2389","article-title":"Deletion of connexin43 in osteoblasts\/osteocytes leads to impaired muscle formation in mice","volume":"30","author":"Shen","year":"2015","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.nmd.2017.05.012_bib0675","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.cmet.2016.05.004","article-title":"Osteocalcin signaling in myofibers is necessary and sufficient for optimum adaptation to exercise","volume":"23","author":"Mera","year":"2016","journal-title":"Cell Metab"}],"container-title":["Neuromuscular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096089661730158X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S096089661730158X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T08:06:39Z","timestamp":1760774799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S096089661730158X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":134,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S096089661730158X"],"URL":"https:\/\/doi.org\/10.1016\/j.nmd.2017.05.012","relation":{},"ISSN":["0960-8966"],"issn-type":[{"value":"0960-8966","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proceedings of a Parent Project Muscular Dystrophy Bone Health Workshop","name":"articletitle","label":"Article Title"},{"value":"Neuromuscular Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmd.2017.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"name":"copyright","label":"Copyright"}]}}